Where Nordic biotech hits the wall — and why Hong Kong is the missing scale
Validated Nordic innovation often stalls at the scale-up gate. Hong Kong is the missing dimension.
14 February 2025Read →
Hong Kong · Nordic life science
SinoNordic LifeCare Fund
A Hong Kong-based investment fund connecting Nordic innovation with Hong Kong healthcare capital.
The dedicated bridge between Nordic life science innovation and Hong Kong capital and markets.
Are you a Nordic life science company seeking capital and Hong Kong access? → For founders
The Thesis
Two ecosystems,
one bridge.
Nordic life science produces world-class innovation that often runs into a capital and market wall. Hong Kong holds vast capital and the world's fastest-growing demand for validated foreign health innovation. We exist to make that connection deliberate, disciplined, and structurally sound — and to share in the value the bridge itself creates, not only in stock-picking.
NordicHong Kong
Nordic innovation → Hong Kong
We give clinically and commercially validated Nordic life science companies access to Hong Kong capital and market entry — a path most cannot build alone.
Hong KongNordic
Hong Kong capital → Nordic
We give Hong Kong investors disciplined, Western-standard access to one of the world's densest health innovation clusters — sourced, vetted, and structured to international norms.
Two ecosystems · one bridge
Nordic
Innovation, quality, trust
Hong Kong
Capital, markets, scale
Life science
Where the science is made
Why Now
Three converging forces define this decade.
01
Nordic innovation density
Output far above its size — a heritage that produced AstraZeneca, Karolinska, and Novo Nordisk, with a deep medtech and biotech base. Yet many companies hit a capital and market wall when they begin to scale.
02
Hong Kong demand
An ageing population, rapidly rising health spending, strong appetite for validated foreign health innovation, and capital actively seeking quality international opportunities.
03
Hong Kong as conduit
Since 2020, a modern and tax-efficient Limited Partnership Fund regime built to channel capital into innovation — paired with one of the world's leading IPO markets as a natural exit.
How we manage the hard parts
Built where most cross-border strategies break.
A bridge is only as strong as the engineering beneath it. Three structural commitments define how we operate.
01
Geopolitics & regulation
Every deal is built to be FDI-screening-compatible from day one. We focus on segments without sensitive dual-use exposure, and structure ownership to withstand regulatory scrutiny on both sides.
02
Capital mobility
Hong Kong domicile was chosen specifically to enable inflow of offshore Hong Kong capital and clean repatriation of returns to Nordic investors — within an internationally recognised framework.
03
Intellectual property
Ownership and core technology are protected within the fund structure. IP is never exposed uncontrolled — a non-negotiable for both portfolio companies and limited partners.
Approach & Structure
Disciplined by design. Phased by intent.
Domicile
Hong Kong Limited Partnership Fund (LPF) — tax-efficient, flexible, and an internationally recognised PE/VC structure.
Phased build
Begin with a selective syndicate / club-deal model — deal-by-deal, no blind pool — to establish track record, then transition to a full LPF once the bridge is proven.
Investor base
Professional investors only: family offices, institutional, and strategic.
Exit
Hong Kong listings, strategic acquisitions, and secondary sales.
Team
The team is the bridge.
Our edge is people who move credibly between a Nordic boardroom and a Hong Kong capital network.
Insights
Perspectives.
Sharp, original thinking on Nordic–Hong Kong life science — from the people building the bridge.
Cross-border health deals under EU FDI screening: a practical map
What the post-2020 EU FDI regime really means for Nordic–Hong Kong life science transactions.
4 March 2025Read →
Why we chose the Hong Kong LPF
Domicile is a thesis. We explain why the Hong Kong Limited Partnership Fund fits ours.
22 March 2025Read →
Illustrative example — not an actual transaction
How it works
How a SinoNordic deal works.
- 01
Source
Identify a clinically and commercially validated Nordic company hitting a scale wall.
- 02
Structure
Establish the Hong Kong vehicle; protect IP and align ownership for cross-border execution.
- 03
Capital + access
Bring Hong Kong capital and a concrete Hong Kong market-entry path — not just a cheque.
- 04
Scale
Execute regulatory, distribution and partnership entry into Hong Kong.
- 05
Exit
Hong Kong listing, strategic acquisition, or secondary sale.
Target profile
The kind of company we build a bridge for.
ValidatedScale-stageClear Hong Kong relevanceDefensible IP
Investor access
Investor access.
Deeper materials — the investor memo and supporting documents — are available to verified professional investors on request.
- Investor memo (PDF)
- Pitch deck
- Structure overview
- Pipeline summary
Contact
Built for investors who want to define the bridge from the start.
The fund is currently seeking a strategic anchor investor. All enquiries are received and handled in confidence.